Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection

[1]  J. Kazura,et al.  Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection , 2012, Malaria Journal.

[2]  N. D. Djadid,et al.  Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-119) in Iranians exposed to unstable malaria transmission , 2010, Malaria Journal.

[3]  I. Mueller,et al.  Treatment with coartem (artemether-lumefantrine) in Papua New Guinea. , 2010, The American journal of tropical medicine and hygiene.

[4]  Jack S. Richards,et al.  The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis , 2010, PLoS medicine.

[5]  A. Djimde,et al.  Understanding the pharmacokinetics of Coartem® , 2009, Malaria Journal.

[6]  J. Kazura,et al.  Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan Adults , 2009, Malaria Journal.

[7]  R. Ploutz-Snyder,et al.  Serological evidence for long‐term epstein–barr virus reactivation in children living in a holoendemic malaria region of Kenya , 2009, Journal of medical virology.

[8]  V. A. Stewart,et al.  Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya , 2009, PloS one.

[9]  P. Gilson,et al.  Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness , 2009, Infection and Immunity.

[10]  M. Lebbad,et al.  Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles , 2008, Malaria Journal.

[11]  R. Chilengi,et al.  Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children , 2008, Malaria Journal.

[12]  John J. Erickson,et al.  Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst‐thiazole orange staining strategy , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[13]  D. Conway,et al.  Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria , 2008, Infection and Immunity.

[14]  J. Soto,et al.  Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. , 2008, The American journal of tropical medicine and hygiene.

[15]  J. Vulule,et al.  A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. , 2007, The American journal of tropical medicine and hygiene.

[16]  David L. Smith,et al.  Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali , 2007, PLoS medicine.

[17]  J. Kazura,et al.  Prenatal Malaria Immune Experience Affects Acquisition of Plasmodium falciparum Merozoite Surface Protein-1 Invasion Inhibitory Antibodies during Infancy1 , 2006, The Journal of Immunology.

[18]  G. Fouda,et al.  Multiplex Assay for Simultaneous Measurement of Antibodies to Multiple Plasmodium falciparum Antigens , 2006, Clinical and Vaccine Immunology.

[19]  Hong Zhou,et al.  Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity , 2006, Infection and Immunity.

[20]  M. Schluchter,et al.  Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. , 2005, The American journal of tropical medicine and hygiene.

[21]  C. John,et al.  Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa1 , 2004, The Journal of Immunology.

[22]  A. Holder,et al.  Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia , 2004, Infection and Immunity.

[23]  S. Howell,et al.  A Single Malaria Merozoite Serine Protease Mediates Shedding of Multiple Surface Proteins by Juxtamembrane Cleavage* , 2003, Journal of Biological Chemistry.

[24]  A. P. Tonon,et al.  Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. , 2003, Gene.

[25]  I. Bygbjerg,et al.  Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. , 2002, Acta tropica.

[26]  A. Holder,et al.  The Human Immune Response to Plasmodium falciparum Includes Both Antibodies That Inhibit Merozoite Surface Protein 1 Secondary Processing and Blocking Antibodies , 2002, Infection and Immunity.

[27]  M. D. Wilson,et al.  Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season , 2001, Parasitology.

[28]  A. Cowman,et al.  Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria , 2001, The Journal of experimental medicine.

[29]  A. Hill,et al.  Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. , 2001, The American journal of tropical medicine and hygiene.

[30]  M. Alpers,et al.  Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea , 2000, Parasitology.

[31]  M. Blackman,et al.  Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. , 2000, Current drug targets.

[32]  D. Conway,et al.  A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses , 2000, Nature Medicine.

[33]  D. Conway,et al.  Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. , 1999, Gene.

[34]  Thomas A. Smith,et al.  6. Multiple Plasmodium falciparum infections in Tanzanian infants , 1999 .

[35]  M Tanner,et al.  Multiple Plasmodium falciparum infections in Tanzanian infants. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  B. Nahlen,et al.  Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. , 1998, Molecular and biochemical parasitology.

[37]  O. Branch,et al.  A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. , 1998, The American journal of tropical medicine and hygiene.

[38]  O. Kaneko,et al.  Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. , 1997, Experimental parasitology.

[39]  G. Snounou,et al.  Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. , 1997, The American journal of tropical medicine and hygiene.

[40]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[41]  C. Long,et al.  Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. , 1995, Molecular and biochemical parasitology.

[42]  O. Branch,et al.  Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. , 1995, Journal of immunology.

[43]  A. Holder,et al.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein , 1994, The Journal of experimental medicine.

[44]  D. Kaslow,et al.  Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. , 1994, Molecular and biochemical parasitology.

[45]  P. Barr,et al.  Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus , 1993, Infection and immunity.

[46]  P. Barr,et al.  A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. , 1992, Journal of immunology.

[47]  A. Holder,et al.  A malaria merozoite surface protein (MSP1)-structure, processing and function. , 1992, Memorias do Instituto Oswaldo Cruz.